Allison Dorval - 21 Jun 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
AVTE
Transactions as of
21 Jun 2022
Transactions value $
$0
Form type
4
Filing time
22 Jun 2022, 17:01:13 UTC
Previous filing
17 Jun 2022
Next filing
01 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +12,500 $0 12,500 21 Jun 2022 Common Stock 12,500 $12.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.